Personalized medicine, personalized intelligence.

Investor Presentation – October 2021

Dr. Alexander Dobranowski
Co-Founder & CEO
Empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce the costs of healthcare.
CONFIDENTIAL & PROPRIETARY INFORMATION
The information contained in this presentation has been prepared by MCI Onehealth Technologies Inc. and its affiliates (the “Company”) for presentation to investors. The information contained in this presentation is confidential and proprietary to the Company. It has been prepared for information purposes with the understanding that, without the prior written consent of the Company, no person will release this presentation or any other document provided herewith or make reproductions of the documents. The information contained in this presentation (a) is provided as at October 13, 2021 and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company.

THIRD PARTY INFORMATION
This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

ELECTRONIC TRANSMISSION
This presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. Neither the Company nor any director, officer, employee or agent of the Company accepts any liability or responsibility whatsoever in respect of any difference between the presentation distributed to you in electronic format and any hard copy version that may be made available to you.

NO OFFERING OF SECURITIES
This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in any jurisdiction.

FORWARD-LOOKING INFORMATION
This presentation includes forward-looking information within the meaning of Canadian securities law. Statements containing words such as “will”, “potential”, “growth”, “goal”, “2022”, “plan”, “adding”, “create”, “increase”, “modernizing”, “expands”, “to offer”, “to join”, “joining”, “strives” and, in each case, their negative and words of similar meaning are intended to identify forward-looking information. Certain statements in this presentation are considered to be forward-looking information, which include statements about the development, launch and growth of different products and services offering by the Company, its strategic objectives, its mid-term financial goals and other matters. By their nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking information will not occur. These assumptions, risks and uncertainties include, among other things, the state of the economy and capital markets, the development of competitive businesses, investments or technologies, the availability of capital and financing, the availability of acquisition opportunities, the Company’s ability to complete acquisitions in its pipeline, trends in the Company’s business or in the technology and health-care services industries, the composition of the Company’s management team, general business, economic and competitive uncertainties, the impact of COVID-19 and the response of governments, regulators, customers and businesses, and other risks that could cause actual results or events to differ materially from those expressed or implied by such forward looking information, including those described under “Risk Factors” in the Company’s prospectus dated December 29, 2020 and its Annual Information Form dated March 31, 2021, copies of which are available on SEDAR at www.sedar.com.

Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. There can be no assurance that the projected results can be realized or that actual results will not be higher or lower than those projected.

Forward-looking information contained in this presentation is based on the current estimates, assumptions, projections, beliefs and expectations of the Company, which the Company believes are reasonable as of the current date, and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Historical information contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. In particular, historical results should not be taken as a representation that such trends will be replicated in the future. All forward-looking information in this presentation is expressly qualified in its entirety by this cautionary statement.

FUTURE-ORIENTED FINANCIAL INFORMATION
To the extent any forward-looking statement in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the Company’s short, medium and long-term growth objectives and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Forward-looking Information”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue, gross margin, EBITDA, adjusted EBITDA, EBITDA margin, net income and other financial results may differ materially from those provided in this presentation. Any such information is presented for illustrative purposes only and may not be an indication of the Company’s actual financial position or results of operations. In this presentation all references to “$” are to Canadian dollars and amounts are stated in Canadian dollars unless otherwise indicated.
Non-GAAP Financial Measures

USE OF NON-GAAP FINANCIAL MEASURES
The Company prepares its financial statements in accordance with International Financial Reporting Standards ("IFRS"). However, this presentation makes use of certain financial measures which have not been prepared in accordance with IFRS, such as earnings before interest, taxes, depreciation and amortization ("EBITDA"), EBITDA Margin, Adjusted EBITDA and Adjusted EBITDA Margin. The Company uses these measures to evaluate the Company’s operating performance as a complement to results provided in accordance with IFRS.

DEFINITIONS, COMPOSITION AND USEFULNESS
EBITDA, EBITDA Margin, Adjusted EBITDA and Adjusted EBITDA Margin are not measures recognized by IFRS and do not have standardized meanings prescribed by IFRS, and therefore may not be comparable to similar measures presented by other companies. The Company’s definition of these measures and management’s assessment of their usefulness are as set out below:

- The information presented in this prospectus includes certain non-IFRS financial measures, namely gross profit, gross margin, EBITDA and EBITDA margin. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS. These non-IFRS measures are used to provide investors with a supplemental measure of the Company’s operating performance and thus highlight trends in the Company’s core business that may not otherwise be apparent when relying solely on IFRS measures. The Company also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. The Company’s management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. The Company believes that each of gross profit, gross margin, EBITDA and EBITDA margin is an important supplemental measure of the Company’s performance, primarily because it and similar measures are used widely among others in the healthcare industry as a means of evaluating a company’s underlying operating performance.
  - “Gross profit” is defined as revenue less cost of physician fees.
  - “Gross margin” is defined as gross profit as a percentage of revenue.
  - "EBITDA" is defined as net income plus the sum of depreciation and amortization, interest on lease liabilities, accretion expense, loss on disposal of property and equipment, income taxes and deferred tax expense minus the sum of gain on sublease contracts and gain on disposal of property and equipment.
  - "EBITDA margin" is defined as EBITDA divided by revenue.

Investors are cautioned that EBITDA, EBITDA Margin, Adjusted EBITDA and Adjusted EBITDA Margin should not be construed as an alternative to net income (loss) determined in accordance with IFRS.

ADDITIONAL INFORMATION & RECONCILIATION
Additional information concerning the Company’s use of non-GAAP financial measures is available in the Company’s management discussion and analysis dated August 16, 2021 for the financial period ended June 30, 2021 ("MD&A") and is incorporated into this presentation by reference. A copy of the MD&A is available under the Company’s profile at www.sedar.com. For a reconciliation of EBITDA, EBITDA Margin, Adjusted EBITDA and Adjusted EBITDA Margin to the nearest comparable IFRS measures, please refer to page 10 of the MD&A and Appendix B of this presentation.
Market Opportunity:

Canadian Family Medicine
- $38B
- CAGR: 3-5%

Canadian Private Healthcare
- $53B
- CAGR: 8-11%

Canadian Corporate Wellness
- $2.7B
- CAGR: 5-6%

North American Data & Analytics
- $300B
- CAGR: 25-30%

“Healthcare is a sector with enormous opportunities, supported by long term demographic trends and fundamentals” - BlackRock
MCI Onehealth is a High-Performance Healthcare Network

25 Clinics
600+ Medical Staff
500+ Corporate Clients
1M+ Annual Patient Visits
2M+ Patient Records
30+ Years of serving patients

Family Medicine (GP)
- 5-10% EBITDA Margin
- Government Pay

Corporate Health Solutions
- 20-35% EBITDA Margin
- Private Pay

Concierge Medicine
- 20-35% EBITDA Margin
- Private + Government Pay

Specialty Health Services
- 10-20% EBITDA Margin
- Government + Private Pay
  - Dermatology
  - Cardiology
  - Endocrinology
  - Mental Health
  - Preventative Medicine
  - Including 30+ Others

Data Analytics Initiatives

Revenue/EBITDA Goals

2020
- $37.3M
- 7.3% Adj. EBITDA Margin

Mid-Term
- >$70M
- 12.17% Adj. EBITDA Margin

Long-Term
- >$200M
- 20-25% Adj. EBITDA Margin

* Adjusted EBITDA is a non-IFRS financial measure. Refer to the non-IFRS Financial Measures section of this document for more information on each non-IFRS financial measure.
Strategic Objectives

Growing our High-Performance Healthcare Network

Adding synergistic medical and digital health services to create better health outcomes and increase higher margin growth

Strategic Value: Revenue, Network & Referral Synergies

Scaling Data and Personalized Medicine Initiatives

Unlocking the value of our clinical data through real world evidence and innovative technology

Strategic Value: High Margin & Global Growth Opportunity

Current Structure

- $37.3M of 2020 Clinic Revenue
- 7.3% 2020 Adj. EBITDA Margin

Mid-Term Goal

- >$70M Target Services Revenue
- 12-17% Adj. EBITDA Margin
Business Transformation

Past MCI Patient Experience

Revenue
Per Patient*:
($30 - 60)

Additional encounters outside network

2021 Tech-Enabled Patient Experience

Revenue
Per Patient*:
($70 - 300)

Additional encounters within network

* Billing Averages based on Ontario Ministry of Health and Internal Company estimates
Adding Data Value to the Mix

Revenue Per Patient*: 
($70 - 300)

* Billing Averages based on Ontario Ministry of Health and Internal Company estimates

2021 Data & Tech-Enabled Patient Experience
Improving the Healthcare Experience

**Patient Experience**

Modernizing the patient experience using **digital health** and virtual care applications and wearables.

**Physician Experience**

Modernizing the physician experience to **improve** patient outcomes and deliver safer patient care.
Potential Value of MCI’s Growing Database**

Typical estimated values per patient record based on recent data transactions:

- **Electronic Health Records**
  - ($35-$330\textsubscript{CDN})

- **Episodic Health Records**
  - ($50 - $1050\textsubscript{CDN})

*Realizing the value of healthcare data: A framework for the future – EY 2019

**Estimated value strictly for illustrative purposes and based off the suggested guidelines in the EY framework for the future 2019
MCI Onehealth 2021: Q2 by the Numbers

Q2 Revenue
$11.8M
Up 53% YOY

Revenue from Corporate Customers up
80%
or $1.27M YOY

Cash and Cash Equivalents
$19.7M
As of Q2 2021

Strategic Acquisitions/Investments
5
Through Q2 2021 with a robust pipeline

Analyst Consensus Revenue Exceeds $60M* for 2022 Based on Strong Organic and Acquired Growth

2022 Revenue Estimates provided by: Canaccord Genuity & Echelon Wealth Partners
Layering Margin Growth

*Refer to forward looking statement disclosure. Goals are not intended to represent guidance.
Executing on Strategy with a Richer Revenue Mix

- 6% Private
- First COVID Lockdown
- 20% Private/Tech
Financial Outlook

2019

- 850,000 patient visits annually
- Predominantly Gov. insured revenue mix
- Approx. $30-60 captured per patient

<table>
<thead>
<tr>
<th>Revenue</th>
<th>$46.3M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Margin*</td>
<td>28-32%</td>
</tr>
<tr>
<td>OPEX</td>
<td>23-24%</td>
</tr>
<tr>
<td>Adj. EBITDA*</td>
<td>5-8%</td>
</tr>
<tr>
<td>Net Income</td>
<td>0%</td>
</tr>
</tbody>
</table>

Mid-Term Goals

- 1.3M + patient visits annually
- Higher margin specialty health, private pay and data analytics revenue mix
- Approx. $70-300 captured per patient visit

<table>
<thead>
<tr>
<th>Revenue</th>
<th>&gt;$70M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Margin*</td>
<td>40-45%</td>
</tr>
<tr>
<td>OPEX</td>
<td>25-28%</td>
</tr>
<tr>
<td>Adj. EBITDA*</td>
<td>12-17%</td>
</tr>
<tr>
<td>Net Income</td>
<td>3-7%</td>
</tr>
</tbody>
</table>

*These are non-GAAP financial measures. Refer to the Non-GAAP Financial Measures section of this document for more information on each non-GAAP financial measure.
Management Team

Dr. Alexander Dobranowski
Co-Founder & CEO

Dr. Dobranowski is a medical doctor with over a decade of experience working at the intersection of healthcare and technology. Previously, as the Clinical Director of Technology at MCI, Dr. Dobranowski led the development and scaling of a number of clinical and patient interfacing applications, including most recently, the development and integration of virtual care platforms for two of Canada’s largest clinic networks.

Mr. Scott Nirenberski
CFO

Mr. Nirenberski served as COO of Globalive Technology, Inc. He has extensive experience in investing and financial operations in the tech sector having spent 23 years in the San Francisco Bay Area. Mr. Nirenberski held various positions running technology investment teams for multibillion dollar funds Pequot Capital and Seasons Capital in addition to being the senior founding partner of Mosaic Asset Management.

Ms. Madeline Walker
President & COO

Mrs. Walker has been involved in MCI OneHealth operations since inception. Previously, she was the COO at TLC vision where she oversaw the growth of the company to become the largest eye care provider in North America, with over $300M in annual revenue.

Ms. Saleema Khimji
CIO

Ms. Khimji is helping shape MCI’s innovation strategy by leveraging her wealth of experience in advancing complex R&D projects. A background in partnerships in the public and private sectors, a legal background and IP expertise, Saleema has worked globally to promote innovation, including as co-inventor of an AI-based sensor technology for pharma and medical applications.
Board of Directors

Dr. Sven Grail  
Co-Chair  
Co-Founder/CEO, Altima Dental

Dr. George Christodoulou  
Co-Chair  
Co-Founder/CEO, Altima Dental

Mr. Kingsley Ward  
Lead Director  
Managing Partner, VRG Capital

Dr. Robert Francis  
Director  
Founder, Regen Scientific and Medcan

Mr. Anthony Lacavera  
Director  
Chair, Globalive Capital  
Founder, WIND Mobile

Mr. Bashar Al-Rehany  
Director  
Former CEO, Euromoney Investment Research

Dr. Alexander Dobranowski  
Director  
Co-Founder & CEO, MCI Onehealth
## Capitalization and Ownership

**June 30th, 2021**

<table>
<thead>
<tr>
<th>CAPITALIZATION</th>
<th>“DRDR” ON TSX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subordinate Class A Voting Shares Outstanding</td>
<td>49,083,537</td>
</tr>
<tr>
<td>Options ($4.59 average ex. price)</td>
<td>4,343,000</td>
</tr>
<tr>
<td>Cash</td>
<td>$19,680,000</td>
</tr>
<tr>
<td>Debt</td>
<td>$0</td>
</tr>
</tbody>
</table>

*36M Class B Multiple Voting Shares not depicted, as they carry no economic value and are non-transferable.

### Ownership Summary (Fully Diluted)

- **49M Shares Outstanding**
  - Directors and Officers: 73.0%
  - Retail and Institutional Shareholders: 27.0%
## Comparable Companies Analysis

| Name                                           | Ticker | Currency | Price  | Market Cap (M) | NTM EV/Sales | FY1 EV/Sales | FY2 EV/Sales | NTM EV/EBITDA | FY1 EV/EBITDA | FY2 EV/EBITDA | NTM EV/FCF | FY1 EV/FCF | FY2 EV/FCF |
|------------------------------------------------|--------|----------|--------|----------------|--------------|--------------|--------------|---------------|--------------|--------------|-------------|------------|------------|------------|
| **Canadian Digital Healthcare Peers**          |        |          |        |                |              |              |              |               |              |              |             |            |            |            |
| CloudMD Software & Services Inc                | DOC.V  | CAD      | $1.78  | 462            | 3.2          | 4.5          | 2.7          | 66.0          | N/A          | 41.8         | NA          | N/A        | N/A        |
| WELL Health Technologies Corp                  | WELL.TO | CAD      | $7.67  | 1661          | 5.8          | 7.8          | 5.0          | 26.5          | 41.7         | 21.8         | 33.2        | 72.1       | 25.0       |
| MindBeacon Holdings Inc                        | MBCN.TO | CAD      | $3.79  | 90            | 1.2          | 1.5          | 1.1          | NA            | NA           | NA           | NA         | NA         | NA         |
| Dialogue Health Technologies Inc                | CARE.TO | CAD      | $9.60  | 613           | 5.5          | 7.1          | 4.9          | NA            | NA           | NA           | NA         | NA         | NA         |
| **Brick and Mortar & Other Health Providers**  |        |          |        |                |              |              |              |               |              |              |             |            |            |            |
| CareRx Corporation                             | CRRX.TO | CAD      | $6.71  | 204           | 0.9          | 1.2          | 0.8          | 8.3           | 12.6         | 6.9          | 23.8        | NA         | 14.1       |
| Skylight Health Group Inc                      | SLHG.V  | CAD      | $4.42  | 157           | 2.9          | 3.5          | 2.6          | 56.7          | NA           | 31.4         | 31.3        | 65.9       | 23.8       |
| Greenbrook TMS Inc                             | GTMS.TO | CAD      | $13.82 | 196           | R            | R            | R            | R             | R            | R            | R          | R          | R          |
| **Clinical Knowledge**                         |        |          |        |                |              |              |              |               |              |              |             |            |            |            |
| Think Research Corporation                     | THNK.V  | CAD      | $2.15  | 112           | R            | R            | R            | R             | R            | R            | R          | R          | R          |
| Akumin Inc                                     | AKU.TO  | CAD      | $3.05  | 220           | 2.0          | 1.9          | 2            | 8.1           | 8.6          | 7.8          | 19.6        | 64.3       | 13.8       |
| VitalHub Corp                                  | VHI.TO  | CAD      | $2.89  | 105           | N/A          | 3.3          | 3.8          | N/A           | 17.4         | 12.4         | N/A        | N/A        | N/A        |
| **US General Healthcare Providers**            |        |          |        |                |              |              |              |               |              |              |             |            |            |            |
| 1Life Healthcare, Inc                         | ONEM    | USD      | $23.72 | 3245          | 5.6          | 6.4          | 5.2          | NA            | NA           | NA           | NA         | 52.8       | NA         |
| Teladoc Health, Inc                            | TDOC    | USD      | $139.17 | 23,048       | 10.1         | 11.9         | 9.2          | 69.4          | NA           | 60.8         | NA         | NA         | NA         |
| IQVIA Holdings Inc                             | IQV     | USD      | $255.29 | 49,756       | 4.2          | 4.4          | 4.1          | 19.2          | 20.3         | 18.6         | 32.7        | 34.4       | 31.8       |
| Veeva Systems Inc                              | VEEV    | USD      | $319.22 | 51,782       | 24.8         | 27.2         | 23.0         | 62.3          | 67.9         | 58.3         | 62.4        | 68.4       | 58.1       |
| Inovalon Holdings Inc                          | INOV    | USD      | $37.84  | 5,704         | 7.9          | 8.5          | 7.5          | 22.1          | 24.3         | 21           | 42.4        | 46.1       | 40.4       |
| Overall                                       |        |          |        |                | 6.18         | 6.86         | 5.53         | 37.6          | 27.54        | 28.08        | 35.06       | 57.71      | 29.57      |
| MCI Onehealth Technologies Inc (Current)       | DRDR.TO | CAD      | $2.64  | 132           | 2.2          | 2.6          | 2.1          | Consensus 2022 Revenue Target: $62.63M |
| MCI Onehealth Technologies Inc (12M Target)    | DRDR.TO | CAD      | $4.00  | 200           | 3.4          | 4            | 3.2          | Consensus 2022 Revenue Target: $62.63M |

**MCI Onehealth Analyst Coverage:**

Doug Taylor  
(416) 867-6101

Rob Goff  
(416) 933-3351
Summary

- Continuing to Grow Canada’s leading High Performance Healthcare Network
- Building Technology Solutions that Drive Better Healthcare Outcomes for all Canadiens
- Creating a Leading Data Analytics Ecosystem
- Poised for Growth with continued Pipeline of Clinical and Data Initiatives
1 Yorkdale Rd, Suite 209, Toronto, Ontario, M6A 3A1 Canada

www.mcionehealth.com

MCI OneHealth Technologies Inc.

Dr. Alexander Dobranowski
Co-Founder & CEO

Mr. Scott Nirenberski
CFO

Mr. Fernando Massalin
Investor Relations

(416) 440-4040 ext. 155
fern@mcionehealth.com
Appendix
MCI Onehealth is a High-Performance Healthcare Network

- **25** Clinics
- **600+** Medical Staff
- **500+** Corporate Clients
- **1M+** Annual Patient Visits
- **2M+** Patient Records
- **30+** Years of serving patients

**Family Medicine (GP)**
Day-to-day point of contact for healthcare

**Corporate Health**
Employee benefits and health programs

**Concierge Medicine**
Private pay healthcare and personalized programs

**Specialty Health Services**
Specialized care for distinct health situations

- Dermatology
- Cardiology
- Endocrinology
- Mental Health
- Preventative Medicine
- Including 30+ Others

**Data Analytics Initiatives**
Using data analytics to improve healthcare

**Revenue/EBITDA Goals**

- **$37.3M** (Adj. EBITDA Margin 7.3%)
- **> $70M** (Adj. EBITDA Margin 12-17%)
- **> $200M** (Adj. EBITDA Margin 20-25%)

* EBITDA and Adjusted EBITDA are non-GAAP financial measures. Refer to the Non-GAAP Financial Measures section of this document for more information on each non-GAAP financial measure.

**Government Pay**
**Private Pay**
**Government + Private Pay**
Acquisition: **Khure Health**

**About Khure Health**

- Khure Health makes it easier for physicians to identify and treat rare and specialty conditions through advanced technology.
- Identifies target patients using global clinical research and deep analytics to help match high-risk patients with the right care pathway.
- Actively working with and/or has rare and specialty disease programs in development with top 10 Pharma companies and international disease associations.

![Data Value]

**Over 300 million patients are affected worldwide and every 1 in 12 Canadians have a rare disorder.**

Get clinical dashboards and tools directly into physician’s hands to improve process.

**Millions of patient screens performed on the Khure Health platform.**

Advanced logic and decisioning based on clinical guidelines and leading peer reviewed research.

**High-Performance Healthcare Network**

- **Family Medicine (GP)**
  - Day-to-day point of contact for healthcare

- **Concierge Medicine**
  - Private pay healthcare and personalized programs

- **Specialty Health Services**
  - Specialized care for distinct health situations

- **Corporate Health**
  - Employee benefits and health programs

**Data Value**

Collection and Structuring of data for institutions.
Acquisition: **Polyclinic**

**About Polyclinic**

- Onsite integrated health services including primary care, specialist care, lab services and an in-house clinical research organization
- Historical annual patient volumes exceeding 100,000 patient visits per year
- Annualized gross revenue in excess of $5.0 million and annualized adjusted EBITDA in excess of $1.0 million*

---

**High-Performance Healthcare Network**

- **Family Medicine (GP)**
  - Day-to-day point of contact for healthcare
- **Concierge Medicine**
  - Private pay healthcare and personalized programs
- **Specialty Health Services**
  - Specialized care for distinct health situations
- **Corporate Health**
  - Employee benefits and health programs
- **Data Value**
  - Collection and Structuring of data for institutions

---

*Has an executive healthcare practice that the Company anticipates can be leveraged by MCI’s client base

Expands MCI’s brick-and-mortar clinic footprint and improves care pathway within MCI ecosystem

Access to more than 50 primary care physicians and specialists, labs, and clinical trials.

An integrated care model that enhances access, quality and efficiency
Investment: **Regen Scientific**

About Regen Scientific

- MCI Onehealth to offer commercial support in long-term partnership with ReGen, a leader in innovation and personalized, preventative, and regenerative health
- Accelerates MCI Onehealth’s strategic vision and roadmap toward a data-driven, modernized technology-enabled health services platform
- MCI nominee to join ReGen’s Board of Directors

---

**Medical Experience focused on personalized treatments**

**ReGen Scientific is expanding your “health span” and corporate health service offering**

**Co-Founder and Founder of Medcan, Dr. Robert Francis to the MCI Onehealth Board of Advisors**

**World-class logistics management and genetic testing laboratory adds level of individualized healthcare**

---

High-Performance Healthcare Network

- **Family Medicine (GP)**
  - Day-to-day point of contact for healthcare
- **Concierge Medicine**
  - Private pay healthcare and personalized programs
- **Specialty Health Services**
  - Specialized care for distinct health situations
- **Corporate Health**
  - Employee benefits and health programs
- **Data Value**
  - Collection and Structuring of data for institutions
Investment: Acorn Biolabs Inc.

About Acorn Biolabs Inc.

• Acorn is a Toronto-based healthcare technology company focused on giving everyone access to the future of cell-based medicine.

• Provides patented non-invasive stem cell collection, analysis and cryopreservation service.

• Acorn helps you prepare for the future of regenerative medicine by banking your best cells today.

Acorn aims to give its patients the ability to live longer, healthier lives through regenerative medicine.

Secure storage and data protection that ensure patient cells remain safe.

MCI will be providing commercial support to Acorn’s innovative solution for live cell collection.

Stem cell therapies work to reduce the severity of a disease or disorders such as Diabetes or MS.

High-Performance Healthcare Network

- Family Medicine (GP)
  - Day-to-day point of contact for healthcare

- Concierge Medicine
  - Private pay healthcare and personalized programs

- Specialty Health Services
  - Specialized care for distinct health situations

- Corporate Health
  - Employee benefits and health programs

- Data Value
  - Collection and Structuring of data for institutions
Investment: Ariel Precision

About Ariel Precision

- A precision medicine platform that is using data insights for the diagnosis and management of complex health conditions
- Ariel analyzes a patient’s genetic data and integrates the patient’s medical history and current symptoms to provide a comprehensive view of the factors that may be contributing to current conditions
- Ariel strives to go beyond genetics, helping clinicians make more informed decisions about the treatment of complex chronic diseases.

Analyzes multiple risk factors that are disease causing rather than just assessing single gene risk factors.

The company has developed the AI-fueled ADVANCE® Platform to identify early symptoms of disease.

Investment establishes a foundation for a collaborative commercial partnership and future entry for MCI into the United States market.

Jessica Gibson, Ariel’s Co-Founder and CEO, joining MCI in an advisory capacity.

High-Performance Healthcare Network

- Family Medicine (GP)
  - Day-to-day point of contact for healthcare

- Concierge Medicine
  - Private pay healthcare and personalized programs

- Specialty Health Services
  - Specialized care for distinct health situations

- Corporate Health
  - Employee benefits and health programs

Data Value

- Collection and Structuring of data for institutions